Search results for "Dara"

showing 10 items of 111 documents

Ofatumumab Combined With Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients With Previously Untreated Chronic Lymphocytic Leukem…

2010

Abstract 207 Introduction: Chemoimmunotherapy regimens have become the treatment standard for patients with CLL. Ofatumumab is a human monoclonal antibody that targets a unique small-loop epitope on CD20 and elicits rapid and efficient in vitro complement-dependent cytotoxicity, as well as antibody-dependent cellular cytotoxicity. Recent studies demonstrated single-agent ofatumumab activity, with high overall response rates (ORR) in patients with refractory CLL. We conducted an international, randomized, parallel group, Phase II trial with two doses of ofatumumab combined with fludarabine and cyclophosphamide (FC) in previously untreated patients with CLL to evaluate the efficacy and tolera…

Cancer Researchmedicine.medical_specialtybusiness.industryMedizinHematologyNeutropeniamedicine.diseaseOfatumumabFludarabineRegimenchemistry.chemical_compoundOncologyTolerabilitychemistryChemoimmunotherapyInternal medicineImmunologymedicineRituximabbusinessFebrile neutropeniamedicine.drugClinical Lymphoma Myeloma and Leukemia
researchProduct

Daratumumab for the Treatment of Multiple Myeloma

2018

This mini-review will summarize the present state of development of the CD38 antibody daratumumab for the treatment of multiple myeloma.

Cytotoxicity Immunologic0301 basic medicineOncologylcsh:Immunologic diseases. Allergymedicine.medical_specialtyAdenosineTreatment outcomeImmunologyDrug Evaluation PreclinicalComplementAntineoplastic AgentsMyelomaimmunomodulationImmunomodulation03 medical and health sciences0302 clinical medicineAntibodies monoclonalimmune system diseasesInternal medicineDaratumumabhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsHumansImmunology and AllergycomplementMultiple myelomaNeonatal Fc-receptorsClinical Trials as Topicbusiness.industryAntibody-Dependent Cell CytotoxicityAntibodies MonoclonalDaratumumabmedicine.diseasedaratumumabTrogocytosis3. Good healthTreatment Outcome030104 developmental biologymyelomaadenosine030220 oncology & carcinogenesisAntibody-dependent cell cytotoxicityMultiple Myelomabusinesslcsh:RC581-607CD38Frontiers in Immunology
researchProduct

Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes

2020

The marine environment is a rich source of biologically active molecules for the treatment of human diseases, especially cancer. The adaptation to unique environmental conditions led marine organisms to evolve di erent pathways than their terrestrial counterparts, thus producing unique chemicals with a broad diversity and complexity. So far, more than 36,000 compounds have been isolated from marine micro- and macro-organisms including but not limited to fungi, bacteria, microalgae, macroalgae, sponges, corals, mollusks and tunicates, with hundreds of new marine natural products (MNPs) being discovered every year.Marine-based pharmaceuticals have started to impactmodern pharmacology and diff…

Eribulin MesylateAquatic OrganismsEnfortumab vedotinLurbinectedinPharmaceutical ScienceAntineoplastic AgentsMarine drugsComputational biologyReviewBiology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSDG 3 - Good Health and Well-beingNeoplasmsmedicineAnimalsHumansSDG 14 - Life Below WaterBrentuximab vedotinlcsh:QH301-705.5Pharmacology Toxicology and Pharmaceutics (miscellaneous)030304 developmental biologyFludarabine Phosphate0303 health sciencesBiological ProductsDrug discoveryDrug discoveryClinical pipelinePolatuzumab vedotinAnticancerlcsh:Biology (General)chemistry030220 oncology & carcinogenesisMarine natural productsMarine ToxinsPlitidepsinWater Microbiologymedicine.drug
researchProduct

Personāla atlases metožu analīze un salīdzināšana uzņēmumā SIA “RIMI Latvia”.

2018

Kvalifikācijas darba zinātniskais vadītājs: lektore, Mg. sc. soc. Inese Pabērza Kvalifikācijas darba temats: Personāla atlases metožu analīze un salīdzināšana uzņēmumā SIA „Rimi Latvia” Kvalifikācijas darba apjoms: 53 lpp, t.sk. 4 tabulas, 9 attēli, 15 pielikumi Kvalifikācijas darbā izmantotie materiāli: Darbā ir izmantota vietējo un ārvalstu autoru literatūra, pētījumi par personāla atlases jautājumiem, publicētie materiāli par SIA „Rimi Latvia” darbinieku meklējumiem, kā arī uzņēmuma nepublicētie materiāli, dažādi interneta resursi un autores veiktās aptaujas dati. Kvalifikācijas darba galvenie rezultāti: Kvalifikācijas darba mērķis ir izpētīt darbinieku atlases procesu mazumtirdzniecības…

JēkabpilsRIMIpersonālsMadaraSabiedrības vadība
researchProduct

Homoseksualitāte Tomasa Manna darba "Nāve Venēcijā"

2022

Tomasa Manna romāna Nāve Venēcijā galvenā varoņa Gustava fon Ašenbaha iekšējā drāma ir viena no noveles galvenajām interesēm. Varonis tiek attēlots kā izcils vācu rakstnieks nobriedušā vecumā, kurš ierodas Itālijas pilsētā Venēcijā un pēkšņi viņu apsēdis daudz jaunāks vīrietis, kamēr varonis bēgot piedzīvo krīzi, sevis atklāšanu un galu galā iznīcību. Savā darbā es vēlos koncentrēties uz homoerotismu un galvenā varoņa pederastikas tēmu. Manā darbā tiks ņemta vērā homoerotisma vēsturiskā poētika, Gustava fon Ašenbaha dzīve un viņa ceļojuma uz Venēciju analīze. Interesanti, ka šogad aprit tieši 110 gadi kopš romāna izdošanas. Lai gan romānā publicētā darba esamība nav tik šokējoša kā tā iznāk…

LGBTValodniecībaLGBT vēsturePedarastijaHomoerotisms
researchProduct

Infrastructura Naturans. Architetture di trasformazione della circonvallazione di Palermo

2022

The article discusses the theoretical system that supports design themes and processes of recycling large urban road infrastructures, referring to an international research that frames them among the sustainable regeneration processes of the contemporary city, and further evoking the project for the transformation of Palermo's ring road that has been elaborated within this research. Witnesses of past urban seasons, these infrastructures are marked by a peculiar morphology that deserves to be maintained, while they must emancipate themselves from asphalt and adapt to new urban mobilities. By hybridizing vegetation and buildings as never before, the longest roadways in our urban contexts may …

L’articolo facendo riferimento ad una ricerca internazionale orientata a definire temi e processi progettuali per il riciclo delle grandi infrastrutture viarie urbane fra i processi di rigenerazione sostenibile della città contemporanea discute il complesso sistema teorico che li orienta anche in rapporto al progetto di trasformazione della circonvallazione di Palermo elaborato in tale ambito. Testimoni di stagioni urbane passate queste infrastrutture possiedono una morfologia peculiare che merita di essere mantenuta mentre devono emanciparsi dall’asfalto e adeguarsi alle nuove mobilità urbane. Ibridando vegetale e costruito come mai prima i più lunghi tracciati viari dei nostri contesti urbani potranno trasformare i loro bordi in nuovi boschi urbani o foreste lineari contrastando le isole di calore e supportando nuovi habitat interspecisti. Le nuove autostrade urbane del futuro non saranno antagoniste dell'architettura o della città come è stato per secoli. Saranno i luoghi di una natura aumentata e pienamente funzionale all'espressione di un nuovo genere urbano non binario fabbricata per rendere le nostre città vivibili come mai prima. Corridoi ecologici vegetazione altre specie clima fonti energetiche rinnovabili daranno corpo a una nuova infrastruttura: una infrastructura naturans.Settore ICAR/14 - Composizione Architettonica E Urbana
researchProduct

1,5-3 gadīgu bērnu adaptācija pirmsskolas izglītības iestādē, to veicinošie un kavējošie faktori

2018

Darba autors: Zane Fetere darba nosaukums: 1,5-3 gadīgu bērnu adaptācija pirmsskolas izglītības iestādē. Veicinošie un kavējošie faktori. Darba zinātniskais vadītājs: Dr. paed., Dagnija Vigule Darba apjoms: 56 lappuses, darbs sastāv no ievada, divām daļām, secinājumiem un pielikumiem. Darbā iekļautas 6 tabulas un 14 attēli, 1 pielikums, izmantoti 52 literatūras un citi informācijas avoti. Pētījuma mērķis: pētīt un analizēt teorijā un praksē 1,5-3 gadīgu bērnu adaptāciju pirmsskolas izglītības iestādē. Hipotēze: 1,5 – 3 gadīgu bērnu adaptācija pirmsskolā būs veiksmīga, ja tiks respektētas mazbērna vecumposma attīstības likumsakarības, notiks veiksmīga pirmsskolas pedagogu un bērnu vecāku sad…

MAZBĒRNA ADAPTĀCIJA PIRMSSKOLAS IZGLĪTĪBAS IESTĀDĒ1-3 GADĪGU BĒRNA ATTĪSTĪBAS LIKUMSAKARĪBASFAKTORI KAS KAVĒ DARA SMAGĀKU BĒRNU ADAPTĀCIJU PIRMSSKOLAS IZGLĪTĪBAS IESTĀDĒSkolas pedagoģijaPRIEKŠNOTEIKUMI VEIKSMĪGAI BĒRNU ADAPTĀCIJAI PIRMSSKOLAS IZGLĪTĪBAS IESTĀDĒ
researchProduct

R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted …

2013

Purpose Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL) requiring treatment, the optimal associated chemotherapy regimen has yet to be clarified. Patients and Methods We conducted an open-label, multicenter, randomized trial among adult patients with previously untreated stages II to IV FL to compare efficacy of eight doses of R associated with eight cycles of cyclophosphamide, vincristine, and prednisone (CVP) or six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or six cycles of fludarabine and mitoxantrone (FM). The principal end point of the study was time to treatment failure (TTF). Results There were 534 patients…

MaleCancer ResearchLymphomamedicine.medical_treatmentFollicular lymphomaCHOPGastroenterologyAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesLymphoma FollicularNON-HODGKINS-LYMPHOMASAdult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Staging; Prednisone; Prognosis; Prospective Studies; Survival Rate; Vidarabine; Vincristine; Oncology; Cancer ResearchCHEMOTHERAPYMiddle AgedPrognosisChemotherapy regimenFludarabineSurvival RateOncologyVincristineFemaleFLUDARABINECLINICAL-TRIALSVidarabinemedicine.drugAdultVincristinemedicine.medical_specialtyAdult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Staging; Prednisone; Prognosis; Prospective Studies; Survival Rate; Vidarabine; VincristineInternal medicinemedicineHumansRITUXIMABSurvival rateCyclophosphamideRESPONSE CRITERIAAgedNeoplasm StagingChemotherapyMitoxantronebusiness.industryFollicularmedicine.diseasePHASE-IIISurgery1ST-LINE TREATMENTDoxorubicinPrednisoneMitoxantroneNeoplasm GradingbusinessFollow-Up StudiesJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Mutations inWNT10Aare frequently involved in oligodontia associated with minor signs of ectodermal dysplasia

2012

Ectodermal dysplasias (ED) are a clinically and genetically heterogeneous group of hereditary disorders that have in common abnormal development of ectodermal derivatives. Hypohidrotic ectodermal dysplasia (HED) is characterized by abnormal development of eccrine sweat glands, hair, and teeth. The X-linked form of the disease, caused by mutations in the EDA gene, represents the majority of patients with the hypohidrotic form. Autosomal dominant and autosomal recessive forms are occasionally seen, and result from mutations in at least three genes (WNT10A, EDAR, or more rarely EDARADD). We have screened for mutations in EDAR (commonly involved in the hypohidrotic form) and WNT10A (involved in…

MaleEctodermal dysplasiaGenotypeMolecular Sequence Datamedicine.disease_causeCompound heterozygosityEctodermal DysplasiaGeneticsmedicineHumansAmino Acid SequenceHypohidrotic ectodermal dysplasiaGenetic Association StudiesGenetics (clinical)AnodontiaGeneticsMutationEDARADDEdar ReceptorGenetic heterogeneitybusiness.industrymedicine.diseaseWnt ProteinsHypodontiaPhenotypeMutationFemaleEctodysplasin AbusinessSequence AlignmentAmerican Journal of Medical Genetics Part A
researchProduct

Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease

2016

We report the outcome of 30 consecutive patients with Hodgkin disease (HD) who underwent single-unit UCBT. Most (90%) patients had failed previous autologous hematopoietic stem cell transplantation. The conditioning regimens were based on combinations of thiotepa, busulfan, cyclophosphamide or fludarabine, and antithymocyte globulin. The cumulative incidence (CI) of myeloid engraftment was 90% [95% confidence interval (C.I.), 74-98%] with a median of 18 d (range, 10-48). CI of acute graft-versus-host disease (GvHD) grades II-IV was 30% (95% C.I., 17-44%), while the incidence of chronic GVHD was 42% (95% C.I., 23-77%). The non-relapse mortality (NRM) at 100 d and 4 yr was 30% (95% C.I., 13-4…

MaleHerpesvirus 4 HumanTransplantation Conditioningmedicine.medical_treatmentGraft vs Host DiseaseHematopoietic stem cell transplantationGastroenterology0302 clinical medicineRecurrencehemic and lymphatic diseasesCumulative incidenceHodgkin's lymphomaIncidence (epidemiology)Graft Survivalumbilical cord blood transplantationHematologyGeneral MedicineMiddle AgedHodgkin DiseaseFludarabine030220 oncology & carcinogenesisAcute DiseaseFemaleCord Blood Stem Cell TransplantationVidarabinemedicine.drugAdultmedicine.medical_specialtyCyclophosphamideThioTEPA03 medical and health sciencesInternal medicinemedicineHumansInfectious MononucleosisBusulfanCyclophosphamideAntilymphocyte Serumbusiness.industryMyeloablative AgonistsHodgkin's lymphomamedicine.diseaseSurvival AnalysisSurgeryEBV post-transplant lymphoproliferative diseaseChronic DiseaseEBV post-transplant lymphoproliferative disease; Hodgkin's disease; Hodgkin's lymphoma; umbilical cord blood transplantationHodgkin's diseasebusinessSettore MED/15 - Malattie del SangueThiotepaBusulfan030215 immunologyEuropean Journal of Haematology
researchProduct